Here's the 1 Key Reason You Might Want to Buy CRISPR Therapeutics Stock on the Dip
It's now a new ballgame for CRISPR Therapeutics (NASDAQ: CRSP). The company, along with its big partner, Vertex Pharmaceuticals (NASDAQ: VRTX), won U.S. regulatory approval for Casgevy (exa-cel) in treating sickle cell disease (SCD) on Dec. 8, 2023. Casgevy picked up U.K. approval for SCD and transfusion-dependent beta thalassemia last month.
Despite the milestone U.S. approval, CRISPR Therapeutics stock sank nearly 19% after the Food and Drug Administration (FDA) made its decision. Shares have rebounded somewhat but remain close to 15% below the previous high.
We could be seeing a textbook case of "buy the rumor, sell the news" with CRISPR Therapeutics. But here's the one key reason why you might want to buy the gene-editing stock on the dip.
Source Fool.com
Vertex Pharmaceuticals Inc. Aktie
Vertex Pharmaceuticals Inc. ist ein klarer Community-Favorit mit mehr Buy- als Sell-Einschätzungen.
Trotz eines Kursziels von 440 €, das unter 452.85 € liegt, ergibt sich für Vertex Pharmaceuticals Inc. ein negatives Potenzial von -2.84%.
